^
Association details:
| Biomarker: | HGF-L |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug Class: | Immunotherapy |
| Direction: | Sensitive |
Evidence:
Source:
Title:
1498P - HGF/MET pathway is associated with poor efficacy of Immune checkpoint inhibitors (ICIs) in advanced-stage NSCLC
Published date:
10/16/2023
Excerpt:
Correlation tests demonstrated that lower HGF levels were associated with a good response to ICIs (RR=2.143; p=0.004) and low progression (RR=0; p=0.01). Patients with low HGF levels (< Q1) at treatment initiation had longer progression-free survival (PFS) (841 vs 136.5 days; HR = 0.26 95% CI 0.1292-0.5411; p=0.0003) and longer overall survival (OS) (median not reached vs. 489 days; HR 0.36; 95% CI 0.1505-0.8408; p=0.02).
Source:
Title:
Plasma Biomarkers Screening by Multiplex ELISA Assay in Patients with Advanced Non-Small Cell Lung Cancer Treated with Immune Checkpoint Inhibitors
Published date:
12/31/2020
Excerpt:
Patients with low sHGF levels at ICIs initiation had longer progression-free survival and overall survival than those with high sHGF levels: respectively 2.5 vs. 8.0 months (p = 0.002), and 5.5 vs. 35.0 months (p = 0.001).
DOI:
10.3390/cancers13010097
